Karyopharm Therapeutics Inc.
KPTI
$8.38
-$0.17-1.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -232.03% | -3.29% | -256.57% | 37.20% | 26.43% |
| Total Depreciation and Amortization | -76.54% | 45.78% | -14.29% | -8.24% | 5.19% |
| Total Amortization of Deferred Charges | 3.73% | 16.66% | 94.70% | 1,137.02% | 986.18% |
| Total Other Non-Cash Items | 1,298.46% | 2,983.14% | 110.51% | -510.15% | -265.25% |
| Change in Net Operating Assets | -41.54% | 35.96% | 206.08% | 85.77% | -49.95% |
| Cash from Operations | 54.17% | 69.88% | 51.43% | 10.84% | -38.88% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -66.09% | -35.71% | -64.33% | -30.93% | -45.07% |
| Cash from Investing | -66.21% | -35.71% | -64.33% | -30.32% | -44.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,246.32% | -- | -53.89% | -- | 157.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,266.47% | -- | -99.13% | -- | 157.58% |
| Foreign Exchange rate Adjustments | 125.00% | -94.44% | 172.73% | 131.25% | -122.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 320.89% | 91.18% | -100.09% | -8.67% | -220.23% |